The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a period of 6 months
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
5mg Nasal Spray
Change in Migraine Disability Assessment questionnaire (MIDAS) score
Time frame: Twice within 28 weeks
Explore patients assessment of value of zolmitriptan
Time frame: Maximum of 3 times between 1 - 28 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.